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echocardiography and hemodynamic indices. Clinical, imaging and proce-
dural characteristics were recorded, and valvular function parameters were
compared at baseline, post procedure, and at 30-days.
RESULTS The study cohort included 161 patients with AS who were
assigned to TAVR with CV. Of these 11 (7%) patients required a second
device implantation at the same procedure due to residual moderate or
severe AR. The mean annular diameter in these patients was 26.7 
2.6 mm. Valve size of the initial valve was 31mm in 8 patients (73%),
29mm in 2 (18%) and 26mm in 1 patient (9%). Average oversizing was 14
 9% and severe valve calciﬁcation on CT was present in 6 patients
(55%). Procedural characteristics demonstrate a low or high initial im-
plantation in 5 (45%) and 2 (18%) of the patients, respectively. Under-
expansion of the initial device was noticed in 6 (54%). The second valve
size matched the ﬁrst valve size in all patients. Immediately post pro-
cedure reduction in AR was noted in all but one patient, with 4 (36%)
patients reaching grade 2 AR and 6 (54%) patients achieving optimal
level of grade 0-1 AR (Figure). Second valve implantation was safe with
no peri-procedural stroke or mortality. However, 6 (55%) patients
developed acute kidney injury, 3 (27%) required pacemaker implanta-
tion and 4 (36%) developed new left bundle branch block.
CONCLUSIONS Second implantation of CV self-expanding valve for the
treatment of signiﬁcant residual AR is feasible and safe and associated with
high immediate success rate, and should be considered as amodality for the
treatment of residual moderate or severe AR after CV implantation.
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been adopted worlwide, but there are still multiple areas where
consensus and evidence are lacking. Post-procedural management
according to the occurrence of conduction disturbances and antith-
rombotic treatment may vary across centers and valve types (balloon
[BEV] and self-expandable [SEV] valve). The objectives of this study
were to determine the real life practice related with post-TAVI man-
agement and antithrombotic treatment across different centers
around the world.
METHODS From January to May 2015, an online survey was distrib-
uted worldwide in centers performing TAVI regardless the number of
procedures and valve type. There was a responsible to distribute the
survey in each country or region.
RESULTS A total of 167 centers (with 37843 TAVI procedures per-
formed) responded the questionnaire from 27 different countries in
Europe, North-America and South-America. Continuous ECG moni-
toring following TAVI was maintained during 24, 48 or 72 hours in
23%, 38% and 39% of the centers, respectively. Temporary pacemaker
was removed at the end of the procedure in the absence of new
conduction disturbances in 27% of patients (45% and 10% following
BEV and SEV implantation, respectively). Transient A-V block occur-
ring during valve implantation was usually not an indication for
permanent pacemaker implantation for both valve types (>70%). New
left bundle branch block was a frequent cause to extend temporary
pacemaker indication (SEV 51%; BEV 41%), but not for permanent
pacemaker implantation (<2% for both valves). Dual antiplatelet
therapy was the most common antithrombotic treatment in patients
without atrial ﬁbrillation (89% of centers), with a variable duration (3
months in 44%, 6 months in 31%). In patients with atrial ﬁbrillation,
warfarin alone, warfarinþaspirin, warfarinþclopidogrel and triple
therapy were given in 35%, 31%, 25% and 3% of the centers, respec-
tively. Patients were followed in a TAVI clinic in only half (46%) of the
centers.
CONCLUSIONS This survey highlights important variations in post-
TAVI management according to ECG monitoring and temporary
pacemaker across centers. Dual antiplatelet therapy is the most
common antithrombotic treatment in the absence of other indication
for anticoagulation, but antithrombotic treatment in patients with
atrial ﬁbrillation is highly variable. Future studies are needed to
determine optimal post-TAVI management and follow-up.
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BACKGROUND Cardiac conduction abnormalities, including left
bundle branch block (LBBB), are not uncommon after TAVR. We
aimed to evaluate the need for permanent pacemaker (PPM) insertion
after development of new LBBB.
METHODS This is a single center study of TAVR patients. Twelve-lead
ECGs were acquired pre- and immediately post procedure, during
hospital stay, and at time of discharge.
RESULTS Of the 528 patients enrolled in study, 95 (18%) initially had
paced rhythm and were excluded. Of the remaining 434 patients, the
incidence of new LBBB was 19%, which was higher in the self-
expanding Medtronic CoreValve compared to Edwards Sapien valve
(Figure 1). Baseline characteristics were similar between those with
and without new LBBB. The median time to development of any new
conduction disease post TAVR was 0 [0, 2] day. New LBBB dis-
appeared in 20 (30%) patients during hospital stay. The time to res-
olution of new LBBB was 2 [1, 5] days. Of all new LBBB, 12 (18%)
progressed to complete heart block (CHB) requiring PMM implanta-
tion. Only 3 (4%) patients required PPM implantation for symptomatic
new LBBB. Of all patients with new LBBB, safety outcomes at 30 days
include: mortality 2 (3%), MI 0 (0%), stroke 2 (4%), and major bleeding
3 (6%). On 30-day follow-up echocardiography, patients with new
LBBB had lower median [IQR] ejection fraction (EF) difference than
